Last reviewed · How we verify
Effect of Taurine on Glycemic, Lipid and Inflammatory Profile in Individuals With Type 2 Diabetes: a Randomized Clinical Trial (TAUGLIP-DM2)
Type 2 diabetes mellitus (DM2) is characterized by chronic hyperglycemia, which is a risk factor for comorbidities and death. Although conventional pharmacotherapy is effective, some individuals do not reach the glycemic targets, requiring adjuvant therapies. Taurine is a semi-essential amino acid with antioxidant and osmoregulatory properties, commonly used as a nutritional supplement. Pre-clinical studies show its effectiveness in reducing blood glucose and cholesterol, but there are no well-conducted clinical studies evaluating the effect of taurine on glycated hemoglobin. Additionally, animal models showed that taurine had a protective effect from diabetic nephropathy. The hypothesize of this study is that taurine administration improves the glycemic, lipid, inflammatory, and anthropometric parameters in DM2 individuals.
Details
| Lead sponsor | Hospital de Clinicas de Porto Alegre |
|---|---|
| Phase | Phase 2 |
| Status | RECRUITING |
| Enrolment | 94 |
| Start date | 2021-06-12 |
| Completion | 2025-12 |
Conditions
- Diabetes Mellitus, Type 2
Interventions
- Active comparator Taurine
- Placebo Comparator
Primary outcomes
- HbA1c — baseline and 12 weeks
Changes from baseline glycated hemoglobin levels at 12 weeks
Countries
Brazil